8. Larimar Therapeutics Inc. (NASDAQ:LRMR)
Larimar Therapeutics Inc. (NASDAQ: LRMR) occupies the eighth position among the best stocks under $10 that could triple, with shares recently trading at approximately $3.69 after gaining 0.54%. The clinical-stage biotechnology company is developing treatments for rare diseases and is currently centered on Nomlabofusp, its experimental therapy for Friedreich’s ataxia.
On June 29, Larimar Therapeutics Inc. (NASDAQ: LRMR) announced that it had submitted the first module of its Biologics License Application to the U.S. Food and Drug Administration. The company is seeking accelerated approval for Nomlabofusp and plans to submit the remaining portions of the application during the second half of 2026.
The beginning of a rolling BLA submission represents a major regulatory milestone for a biotechnology company. Rather than waiting until every section of the application is complete, a rolling submission can allow the FDA to begin reviewing certain modules while the company prepares the rest. This can make the regulatory process more efficient, although it does not guarantee approval.
Larimar Therapeutics Inc. (NASDAQ: LRMR) is pursuing accelerated approval, a regulatory pathway intended for treatments that address serious conditions and may provide meaningful advantages over available therapies. Under this approach, the FDA can consider approving a treatment based on a surrogate endpoint that is reasonably likely to predict clinical benefit.
In the case of Nomlabofusp, the company is relying on skin frataxin as a new surrogate endpoint. Frataxin is a protein that is deficient in people with Friedreich’s ataxia. The disease is a rare inherited disorder that progressively damages the nervous system and can lead to problems with movement, balance, speech, heart function, and other essential activities.
Larimar Therapeutics Inc. (NASDAQ: LRMR) also reported positive findings from an open-label study involving adult patients who received daily injections of Nomlabofusp. The treatment is designed to deliver frataxin into the mitochondria of patients’ cells, addressing the underlying protein deficiency associated with Friedreich’s ataxia.
President and Chief Executive Officer Carole Ben-Maimon described the data as an important advancement in the development of the therapy. According to the company, the FDA confirmed that the existing data package could support an accelerated approval application using skin frataxin as the surrogate endpoint.
This regulatory alignment is a significant part of the bullish case for Larimar Therapeutics Inc. (NASDAQ: LRMR). Smaller biotechnology companies can lose substantial time and capital when regulators require additional studies or disagree with a proposed approval pathway. Clearer communication from the FDA can reduce some uncertainty and help management focus its resources on completing the application.
Still, accelerated approval is not a shortcut around the need to prove that a therapy works. Companies that receive accelerated approval are generally required to complete confirmatory studies to verify the expected clinical benefit. If those trials fail, are delayed, or do not confirm the treatment’s effectiveness, regulators can take steps to restrict or withdraw the product.
On June 30, Baird analyst Christopher Chen reduced his price target for Larimar Therapeutics Inc. (NASDAQ: LRMR) from $7 to $5. Despite the downward revision, the $5 target still represented potential upside of more than 53% from the prevailing share price. Chen also reiterated an Outperform rating on the stock.
The analyst revised the firm’s financial and valuation model following the company’s update on Nomlabofusp. The new information appeared to support potential clinical benefits but also raised safety considerations that investors will need to watch carefully.
Safety is especially important for a therapy intended for chronic or repeated administration. Even when a drug shows biological activity, regulators and physicians must determine whether its benefits outweigh its risks. Any serious adverse events, dosing limitations, immune reactions, or treatment-related complications could affect Nomlabofusp’s approval prospects and commercial adoption.
Larimar Therapeutics Inc. (NASDAQ: LRMR) describes itself as a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using a cell-penetrating peptide technology platform. Its lead program, also known as CTI-1601 or Nomlabofusp, is being evaluated through ongoing clinical development, including a Phase 2 open-label extension program.
The company’s technology is designed to transport functional proteins into cells and direct them toward specific cellular compartments. In theory, such an approach could eventually have applications beyond Friedreich’s ataxia, although the immediate investment thesis remains tied overwhelmingly to Nomlabofusp.
That concentration creates both opportunity and risk. If Nomlabofusp receives approval and demonstrates meaningful benefits for patients, Larimar Therapeutics Inc. (NASDAQ: LRMR) could gain access to a rare-disease market with significant unmet need and limited treatment options. Rare-disease therapies can command premium pricing because they address small patient populations and often require specialized development programs.
On the other hand, a regulatory setback or major safety concern involving Nomlabofusp could have an outsized effect on the company’s valuation. Investors considering Larimar Therapeutics Inc. (NASDAQ: LRMR) should therefore follow the completion of the BLA submission, FDA feedback, safety data, confirmatory trial requirements, manufacturing readiness, and the company’s cash position.
For investors looking for rare-disease stocks, biotechnology stocks under $5, or clinical-stage stocks with regulatory catalysts, Larimar Therapeutics Inc. (NASDAQ: LRMR) deserves attention. However, it remains a speculative investment whose performance will likely be determined by regulatory execution and the clinical profile of one primary treatment candidate.
Click next to see the following stock...
